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Abstract 
 
Parkinson’s disease is a fatal and incurable human 
neurodegenerative disorder that destroys midbrain 
neurons. The misfolding, accumulation, and aggregation 
of the protein α-synuclein is thought to kill these cells. 
Enhancing α-synuclein degradation may help prevent its 
accumulation and aggregation, while protecting cells 
against toxicity. For this thesis, we used the model 
organism budding yeast to evaluate the hypothesis that 
α-synuclein is degraded by the cellular organelle 
lysosome via a specific route: the MVB/endocytosis 
pathway. Specifically, we evaluated whether three 
disease-related properties of α-synuclein (aggregation, 
accumulation, and toxicity) worsened in yeast strains 
that were individually deleted for genes coding for 
proteins required for the MVB/endocytosis pathway. In 
support of our hypothesis, each gene deletion altered 
one or more α-synuclein properties. While our data 
indicates that the MVB pathway is a route for α-
synuclein degradation, the specificity and extent of α-
synuclein involvement with proteins within the ESCRT 
complexes appears unexpectedly complex. 
 
Introduction  
 
Neurodegenerative Diseases 
The human brain is considered the most extraordinarily 
complex organ to have evolved in all living organisms. It is 
thought to control all behaviors, from simple movements and 
sensations to attributes as complex as emotions, language, 
culture, and personality. Due to the brain’s complexity, it is 
logical that the malfunction of its neurons leads to tragic 
illnesses, including addiction, autism, depression, and 
schizophrenia. Among such brain disorders, 
neurodegenerative diseases are a specific family of 
devastating and fatal ailments that result from the 
progressive death of specific neurons. There is no cure for 
these diseases, and they affect millions of people worldwide. 
Sadly, the longer we live the more these diseases become a 
burden on society’s healthcare and economy.  
 The major neurodegenerative diseases are 
Alzheimer’s disease (AD), Huntington disease (HD), prion 
diseases, Lou Gehrig’s disease (ALS), and Parkinson’s 
disease (PD). In each disease, a different set of neurons 
dies interrupting highly specialized networks in the brain 
controlling unique functions like learning and memory (in 
AD), initiation and termination of movement (in PD or HD) or 
muscle control (in ALS). In addition to cell death, the 
pathogenesis of these neurodegenerative diseases is linked 
to another common signature: the misfolding of a specific 
protein unique to each disease (Figure 1A). Such abnormal 
protein deposits may result in amyloid plaques outside dying 
cells (AD and prion diseases) or cytoplasmic inclusions 
inside dying cells (HD and PD; Taylor et al., 2002). Despite 
substantial progress during the past decade, many biological 
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mysteries linking protein misfolding and cellular death 
remain unsolved. My thesis focuses on better understanding 
the molecular basis of one neurodegenerative disease: PD. 
Insight into Parkinson’s Disease   
 Although all neurodegenerative diseases are fatal, 
Parkinson’s disease is among the most devastating due to 
its high occurrence in the adult population. In fact, PD is the 
second most common neurodegenerative disease, affecting 
over one million people in North America (Greenamyre and 
Hastings, 2004). PD patients suffer from the selective loss of 
dopaminergic neurons in a region of the brain known as the 
substantia nigra. Loss of these specific cells contributes to 
the onset of PD symptoms, such as resting tremors, 
slowness in movement, and muscular rigidity (Forno, 1996; 
Olanow and Tatton, 1999). These neurons form part of the 
nigrostriatal pathway in the basal ganglia and project from 
the substantia nigra to the striatum, a structure that controls 
timing and coordination of movement. Additionally, neurons 
in this region synthesize the neurotransmitter dopamine, 
which controls signaling in the basal ganglia. Thus, loss of 
dopamine production results in motor deficiency (Figure 1B). 
 As a member of the neurodegenerative disease 
family, PD is characterized not only by cell death, but also by 
the presence of protein inclusions in the dying neurons that 
control movement. Post mortem examination of PD brains 
reveals the presence of aggregates composed mainly of two 
proteins, α-synuclein and ubiquitin. These deposits, termed 
Lewy bodies, are found in both sporadic and familial cases 
of PD (Lücking and Brice, 2000; Spillantini et al., 1998). Over 
ninety percent of PD cases are sporadic. This form of PD is 
commonly linked to the misfolding of normal α-synuclein, 
however, its cause is not well understood. Furthermore, 
some sporadic cases are caused by environmental toxins, 
such as MPTP and pesticides (Langston et al., 1983; 
Dawson and Dawson, 2003; Greenamyre and Hastings, 
2004). 
 Alternatively, a second form of PD known as 
familial PD, is inherited due to its genetic component. Unlike 
sporadic cases, aggregates in familial PD contain one of 
three mutant α-synuclein proteins caused by point mutations 
in the α-synuclein gene (A30P, A53T, or E46K; 
Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et 
al., 2004). Furthermore, familial cases of PD have also been 
linked to mutations in five other genes. These mutations 
have served as genetic tools that provide evidence that 
oxidative stress and proteasomal dysfunction are linked to 
PD pathogenesis. The role of mitochondrial oxidative stress 
is supported by mutations in the DJ-1 protein, and the 
mitochondrial protein and associated protein PINK-1 and 
LRRK2 (Bonifati et al., 2003; Paisan-Ruiz et al., 2004; 
Valente et al., 2004; Zimprich et al., 2004). Studies 
concerning mutations in ubiquitin proteasome system (UPS) 
proteins UCH-L1 and parkin support the proteasomal 
dysfunction hypothesis (Kitada et al., 1998; Funayama et al., 
2002). The study of these five mutations provides insight into 
the possible mechanisms underlying sporadic PD. More 
specifically, scientists believe that oxidative stress and/or an 
impaired ubiquitin-proteasome system could also contribute 
to sporadic forms of PD. However, given the invariant 
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Figure 1: Neurodegenerative diseases. A. Neurodegenerative diseases are characterized by cell death; however, they are also characterized by a 
common problem: protein misfolding. Each disease has a culprit protein that misfolds and accumulates. B. Parkinson’s Disease Pathway. The motor 
cortex controls movement of our muscles, and the basal ganglia controls timing and coordination of that movement. In PD, dopaminergic neurons in 
the substantia nigra (SNpc) die (X). Death on these neurons leads to dopamine deficiency. A decline in dopamine levels interrupts the nigrostriatal 
pathway causing less voluntary movement.  
 
 
presence of misfolded and aggregated α-synuclein in both 
forms of PD, it appears critical to discuss its role in the 
pathogenesis of this disease. 
 
What is α-Synuclein?   
The culprit protein in all forms of PD is α-synuclein. This 
protein, which is found to aggregate in all PD patients, is 140 
amino acids in length and is commonly found in presynaptic  
 
 
terminals of substantia nigra neurons (Maroteaux et al., 
1988; Kaplan et al., 2003). Although its function is unknown, 
α-synuclein colocalizes with synaptic vesicles and is thought 
to regulate vesicular transport (Cabin et al., 2002; Outerio 
and Lindquist, 2003).  As previously mentioned, α-synuclein 
misfolding can result from genetic mutations or a random 
event in the normal α-synuclein protein leading to the 
formation of Lewy bodies. In vitro studies show that both 
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  wild-type and mutant α-synuclein are capable of self-
fibrillation. However, mutant forms of this protein are more 
likely to aggregate (Conway et al., 1998; Giasson et al., 
1999; Conway., et al 2000).  
 The process of protein misfolding and aggregation 
begins with the accumulation of individual proteins. This 
phenomenon can be explained by the nucleation 
polymerization model, which states that protein monomers 
form aggregated polymers over time (Conway et al., 2000). 
Fibers form much more quickly if preformed proteins fibers 
are present.  Furthermore, this model accounts for the 
protein misfolding observed in other neurodegenerative 
diseases, such as b-amyloid  in Alzheimer’s disease, 
huntingtin in Huntington’s disease, and prion proteins in 
Creutzfeld-Jacob disease (Caughey and Lansbury, 2003; 
Perutz and Windle, 2001). We are thus left with the question, 
does protein misfolding play a role in disease pathogenesis? 
 In addition to forming aggregates, α-synuclein 
tends to interact with phospholipid membranes and, like 
other phospholipid-binding proteins, it contains a cytosolic 
fatty acid binding signature (Sharon et al., 2001). Upon 
interaction with lipids, α-synuclein which is normally unfolded 
in cells, adopts a helical conformation (Eleizer et al., 2001). 
Both in vitro and in vivo studies confirm α-synuclein’s 
phospholipid and vesicle binding characteristics (Davidson et 
al., 1998; Jo et al., 2000; Eliezer et al., 2001). Furthermore, 
membrane-localized α-synuclein is observed in rat and 
budding yeast models (Maroteaux and Scheller, 1991; 
Outerio and Lindquist, 2003, Dixon et al., 2005; Sharma et 
al., 2006). In the past, studies have shown that both α-
synuclein aggregation and membrane-binding are linked to 
PD pathogenesis. One model suggests that aggregated 
forms of α-synuclein enhance toxicity in cells, while another 
argues that plasma membrane localization correlates with 
increased toxicity (Goldberg and Lansbury, 2000; Dixon et 
al., 2005; Chua and Tang, 2006). A complete understanding 
of α-synuclein’s aggregate and membrane binding 
properties, and their role in PD pathogenesis, remains an 
unsolved mystery.  
 Throughout the past decade extensive work 
focused on characterizing the mutant forms of α-synuclein. 
Similarly to wild-type (WT) α-synuclein, familial mutants 
A53T and E46K localize to the plasma membrane in yeast 
(Outerio and Linquist, 2003; Dixon et al., 2005; Sharma et 
al., 2006; White thesis, 2007). In contrast, A30P has reduced 
membrane localization and is found diffuse throughout the 
cytoplasm (Dixon et al., 2005; Sharma et al., 2006). 
Overexpression of WT and A53T α-synuclein is toxic to 
yeast cells. However, whereas A53T α-synuclein transgenic 
mice form neuronal inclusions leading to the paralysis and 
death, WT α-synuclein transgenic mice remain unaffected 
(Outerio and Linquist, 2003; Dixon et al., 2005; Giasson et 
al., 2003). The last familial mutant, A30P, generates only 
subtle toxicity in yeast (Outerio and Linquist, 2003; Dixon et 
al., 2005).  
 
The Five Conundrums  
Although the past decade celebrated many advances in the 
field, five key questions concerning the molecular basis of 
PD remain unanswered. Firstly, it is still unclear whether α-
synuclein is implicated in PD pathogenesis. Secondly, the 
mechanism regulating α-synuclein misfolding and 
aggregation is not well understood. Furthermore, if α-
synuclein is the causative agent in PD, then its toxic form, 
whether membrane-bound or aggregated, remains unclear. 
Thirdly, we are unaware of the specific relationship between 
the ubiquitin-proteaseome (UPS) degradation pathway and 
α-synuclein. It is unknown whether UPS deficiency leads to 
α-synuclein aggregation or if α-synuclein impedes UPS 
function in PD patients. Fourthly, further research is needed 
to elucidate the role of oxidative stress in PD pathogenesis. 
Finally, all routes for α-synuclein degradation have not yet been 
established. Since α-synuclein is present in all forms of PD, 
understanding its degradation pathway could shed light on how 
to enhance its removal, which may be a possible target for 
therapy. This last question will be the focus of my thesis. More 
specifically, I investigated the MVB/endocytosis pathway as an 
alternative route for α-synuclein degradation.  
Cells must remove damaged or aged proteins to 
maintain proper function. In cells, degradation can occur in one 
of two sites: the proteasome or the lysosome. The proteasome 
is a protein complex located throughout the cell that degrades 
nuclear or cytoplasmic proteins; the lysosome is a membrane-
bound organelle consisting of an acidic lumen where proteolysis 
of extracellular or membrane-bound proteins occurs (Figure 2).  
 
Proteasome: A Known Route for α-Synuclein Degradation 
For the past fifteen years, studies suggested that α-synuclein 
was degraded strictly by the proteasome. This assumption 
was supported primarily by mutations in two genes encoding 
proteins involved in the ubiquitin-proteasome system: 
UCHL1 and parkin. Mutations in either of these genes are 
known to cause familial PD. UCHL1 is a proteolytic enzyme, 
and an increase in its activity inhibits proteasomal 
degradation of α-synuclein (Funayama et al., 2002; Liu et al., 
2002). Parkin is an E3 ubiquitin ligase essential for the 
attachment of ubiquitin to damaged proteins, signaling their 
degradation (Kitada et al., 1996). More importantly, 
mutations in the parkin gene are toxic to neurons in the 
substantia nigra. Additionally, the neurons expressing 
mutant forms of parkin accumulate non-ubiquitinated α-
synuclein (Giasson and Lee, 2001). These observations 
suggest that parkin is needed to add ubiquitin molecules to 
α-synuclein in order for α-synuclein’s degradation to occur.  
Another line of evidence for α-synuclein degradation via the 
proteasome lies in in vitro and in vivo studies, which 
demonstrate that pharmacological inhibition of the 
proteasome leads to the selective loss of dopaminergic 
neurons in mice and the death of rat adrenal medulla cells 
(Nair et al., 2006; Rideout et al., 2002). Furthermore, 
inhibition of proteolytic activity in 26/20S proteasomes and 
UCHL1 induces α-synuclein aggregation and toxicity 
(Mytilineou et al., 2004). Proteasome inhibition in mice 
increases cytoplasmic p53, a protein involved in apoptotic 
signaling. This suggests that the p53 pathway may be 
relevant to the neurodegeneration seen PD patients (Nair et 
al., 2006). Also, rat adrenal medulla cells expressing A53T 
α-synuclein show diminished proteasomal activity, and 
symptomatic α-synuclein transgenic mice express similar 
deficiencies in the UPS as patients with sporadic forms of 
PD (Goedert, 2001; Stefanis et al., 2001; Chen et al., 2006). 
Proteasomal defects in A53T-expressing cells are possibly 
explained by the early appearance of mutant α-synuclein 
inclusions.  
 
Lysosome: An Alternative Route for α-Synuclein Degradation 
Until recently, the proteasome was thought to be the only 
site for α-synuclein turnover. However, mounting evidence 
suggests that the lysosome is also responsible for α-
synuclein degradation. Damaged proteins take one of two 
routes when targeted for lysosomal degradation: autophagy 
or endocytosis. Furthermore, a biosynthetic route known as 
the cytoplasm-to-vacuole pathway is also capable of 
transporting cytosolic proteins, such as Aminopeptidase I 
(API), to the lysosome for degradation (Scott and Klionsky, 
1995; Scott et al., 1996; Figure 3A). 
Some of the first studies that contribute to the idea 
that the lysosome is a site for α-synuclein degradation were 
conducted by Cuervo et al. (2004). Cuervo and his  
 
	   
	  
Figure 2: Degradation routes for misfolded proteins. DNA molecules code for specific amino acid sequences that determine the shape of all proteins found in 
our cells. Usually proteins fold into their correct structure and help maintain order in cells. However, sometimes proteins misfold and are a threat to the cell. 
Although normal proteins can misfold, this is more common when a mutation is present. Misfolded proteins can be degraded by the lysosome or the proteasome. 
Damaged proteins found in the cytoplasm or the nucleus are degraded by the proteasome, whereas extracellular or membrane proteins are degraded by the 
lysosome. Unfortunately, when misfolded proteins are unable to be degraded they may aggregate and accumulate and in many cases cause cell death. This can 
also occur if the proteasome and/or lysosome are compromised. 
 
 
colleagues found that when rat midbrain neuron cultures 
were treated with the protease inhibitor expoxomicin or the 
lysosome inhibitor ammonium chloride, only cells with 
impaired lysosomes accumulated endogenous and human 
WT α-synuclein. Interestingly, cells with impaired 
proteasomes were able to properly degrade WT α-synuclein. 
This study suggests that, while WT α-synuclein is degraded 
in the lysosome by chaperone-mediated autophagy (CMA), 
mutant α-synuclein A30P and A53T block CMA and are not 
properly degraded by the lysosome (Cuevro et al., 2004). 
Moreover, lysosomal inhibition in non-neuronal cells, 
differentiated neuroblastoma cells, and primary cortico 
neurons lead to α-synuclein accumulation and aggregation 
(Lee et al., 2004). 
The aforementioned studies reinforce the notion that 
the lysosome is a site for α-synuclein degradation. However, 
evidence was primarily focused on chaperone-mediated 
autophagy; in fact, research in the field neglected the possibility 
that the second route, the endocytosis/lysosome pathway, could 
also mediate α-synuclein degradation.  
The endocytosis pathway is relevant because a 
genetic screen in yeast revealed that specific knockouts of 
essential endocytotic proteins increase α-synuclein toxicity 
(Willingham et al., 2003). Three out of the 86 genes found to be 
toxic encoded vesicular transporting proteins (vps) vps24, 
vps26, and vps28. Similarly, recent studies provide evidence, 
which suggests that deficient endocytosis is linked to PD 
pathogenesis (Kuwahara et al., 2008). They found that the loss  
 
 
 
of four endocytosis-related genes (pa-2, aps-2, eps-8, rab-7) 
caused neurons to accumulate α-synuclein in C. elegans. 
Furthermore, these neurons had impaired neuromuscular 
transmission causing the worms to exhibit motor impairments.  
 
Multivesicular Body/Endosome Pathway 
Protein transport within the endocytosis pathway depends on 
the formation of multivesicular bodies (MVB). Multivesicular 
bodies are essential compartmentalizing vesicles that have 
multiple functions within a cell. Studies in Drosophila and C. 
elegans demonstrate the role of MVB in regulating development 
and neuronal differentiation (Artavanis-Tsakonas et al., 1999; 
Berset et al., 2001). The study of the MVB pathway is also 
important for understanding other related mechanisms, such as 
budding of viruses. This is of importance because HIV-1, for 
example, follows a process of the MVB pathway (Strack et al., 
2000).   
Endocytosis is a route taken by transmembrane 
proteins to reach the lysosome for degradation. Many proteins 
have cytoplasmic domains that mediate their ability to be 
removed by endocytosis. For example, epidermal growth factor 
receptor (EGFR), a well-characterized substrate for this 
pathway, contains such a domain. However, a mutation in the 
domain inhibits proper endocytosis and ultimately, degradation 
of the protein (Felder et al., 1990). In addition, yeast proteins 
Ste3, Gap1, Tat2t and mammalian proteins GHR, MHCII, E-
Cadherin are tagged with ubiquitin and transported to the 
lysosome by the MVB sorting pathway (Katzmann et al., 2002). 
Lysosomal degradation of Ste2p, also a cell surface protein, in  
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Figure 3: MVB/Endocytosis pathway A. Two major and one minor routes for lysosome degradation: (I) Endocytosis: Plasma membranes invaginate to isolate 
damaged or old membrane proteins in a vesicle called an endosome. Proteins are then sorted into compartments within the endosome to create a multivesicular 
body. Fusion between multivesicular bodies and the lysosome is the last step to transport the protein into the lysosome for its degradation. (II) Autophagy: 
Damaged proteins in the cytoplasm are engulfed by an autophagosome, which is then transported to the lysosome. Fusion between the two allows the damaged 
protein to be transported into the lysosome. (III) Cytoplasm-to-vacuole (Ctv): This is a biosynthetic pathway similar to autophagy. Damaged enzymes in the 
cytoplasm are engulfed by a membrane creating a vesicle to transport the enzyme to the lysosome for degradation. B. Early endosomes recruit ESCRT-I (vps28, 
vps23, vps32, mvb12), ESCRT-II (vps25, vps36, vps22), and ESCRT-III (vps24, vps20, vps2, vps32) complexes to their membrane. The damaged protein 
(cargo) binds to ESCRT-I and is transported from one complex to the next (following the arrows) until it is ready to be engulfed by the endosome membrane. 
Once in a separate compartment within endosome the structure is a multivesicular body (MVB). MVBs then fuse with the lysosome.
 
 
S. cerevisiae was the first to be studied closely to monitor the 
role of ubiquitin in this pathway.  In order for proteins to be 
correctly sorted into the lysosome, they must first be tagged with 
ubiquitin. Endocytosis initiates after the cytoplasmic domain of 
transmembrane proteins undergo monoubiquitylation (Hicke, 
2001; Hicke and Dunn, 2003; Strous et al., 1996). 
Membranescontaining ubiquitin-tagged proteins will create early 
endosomes by invagination. However, if all Ste2 lysine residues 
are mutated, ubiquitin cannot bind to it, and the protein is not 
degraded (Terrell et al., 1998). 
Sorting of proteins into multivesicular bodies (MVB) is 
a complex process facilitated by the interactions between many 
endosomal sorting complexes required for transport (ESCRT). 
These sorting complexes are found on the MVB membrane and 
consist of vacuolar protein sorting (vps) proteins, which help 
transport the damaged cargo across the MVB membrane. Each  
 
 
complex consists of specialized class E vacuolar (vps) proteins. 
ESCRT-I is made up of vps37, vps28, vps23 and mvb12 (Alam 
and Sundquist, 2007). Of these four proteins vps28 physically 
interacts with ESCRT-II, which consists of vps22, vps36 and two 
vps25 subunits (Babst et al., 2002; Hierro et al., 2004). Finally, 
ESCRT-III is made up of vps2, vps20, vps24 and vps32. 
ESCRT-II and ESCRT-III psychically interact via the binding 
between vps25 and vps20 (Babst et al 2002; Hurley, 2006). 
Although, studies were performed in a simple, unicellular 
fungus, other research suggests that the pathway is highly 
conserved between yeast and humans (Katzmann et al., 2001).  
These vps proteins have numerous interactions with 
each other. Studies using budding yeast as a model show that 
vps27 is recruited by vps24 on the endosome membrane where 
it binds to the ubiquitinated cargo. Simultaneously, vps27 
recruits ESCRT-I (Piper et al., 1995; Katzmann et al., 2001; 
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  Katzmann et al., 2003). Interaction between monoubiquitinated 
cargo and ESCRT-I will recruit ESCRT-II and ESCRT-III to the 
membrane. Recruiting all three ESCRT complexes enables the 
monoubiquitinated cargo to be transported across the 
membrane so that it can then invaginate and deposit the cargo 
into vesicles within the endosome’s lumen (Babts et al., 2002). 
Damaged cargo is sorted into compartments within the 
endosome, which give rise to the multivesicular body. This MVB 
then fuses with the lysosome and deposits its contents allowing 
for cargo proteolysis. All substrates of the MVB/endocytosis 
pathway take the same route. However, our question is specific 
to one possible substrate: α-synuclein. 
 
Gap in Knowledge: What We Still Do Not Know 
Although past evidence for lysosomal degradation of α-
synuclein exists, research has been limited to only 
pharmacological studies (Cuervo et al., 2004; Lee et al., 2004). 
Furthermore, proteasomal degradation of α-synuclein, a well 
studied route, is supported by pharmacological, genetic, and 
biochemical evidence. Thus, in order to recognize the lysosome 
as a site for α-synuclein degradation genetic and biochemical 
studies are also needed. Until now, only one study showed α-
synuclein toxicity in endocytosis-deficient strains (Willingham et 
al., 2003). Independent confirmation for the toxicity observations 
is still needed. Furthermore, not all PD-linked α-synuclein 
properties, such as localization and accumulation, were 
previously evaluated. In addition, whether MVB/endocytosis 
protein complexes are utilized similarly by all protein substrates 
is poorly analyzed. Lastly, if α-synuclein uses this pathway, it is 
unknown whether all protein or protein complexes will be critical. 
My thesis intends to fill this gap in knowledge using a budding 
yeast model.  
 
Why Budding Yeast? 
I used a S. cerevisiae model in order to evaluate the role of the 
MVB to lysosome pathway in regulating α-synuclein toxicity, 
expression, and localization. This eukaryotic model system is an 
effective tool for the study of neurodegenerative disorders and 
protein misfolding. Budding yeast are employed in the study of 
Huntington’s disease, (Krobitsch and Lindquist, 2002; 
Willingham et al., 2003), prion diseases (Ma and Lindquist, 
1999) and Parkinson’s disease (Outerio and Lindquist, 2003). 
Most importantly, this model is relevant in that the MVB to 
lysosome pathway is highly conserved between humans and 
yeast (Katzmann et al., 2001). Additionally, the pathway and 
proteins involved in the process of endocytosis were first studied 
in S. cerevisiae and are best studied in yeast (Katzmann et al., 
2002). Budding yeasts are practical organisms to analyze the 
role of the MVB to lysosome pathway in α-synuclein degradation 
because yeast vacuoles are analogous to human lysosomes 
(Kim and Klionsky, 2000). Finally, the complete yeast knockout 
and overexpression library is available, providing means to 
properly evaluate the genetic component of the MVB/lysosome 
pathway and α-synuclein (OpenBiosystems). More specifically, 
a single gene can be removed from the yeast allowing us to 
assess its role in regulating α-synuclein. 
The first yeast model for PD was established by 
Outerio and Lindquist (2003). They found that WT and A53T α-
synuclein bound the membrane, was toxic and disrupts 
vesicle pools. A30P, however, was diffuse throughout the 
cytoplasm and not toxic. These findings were then confirmed 
by Dixon et al. (2005). Many genetic screens have been 
conducted in hopes of finding α-synuclein toxicity 
suppressors. It was found that, when deleted, 86 genes 
enhanced toxicity (Willingham et al., 2003).  
Our lab has been successful in using yeast as a 
model organism for studying the following PD-related α-
synuclein properties: toxicity, expression levels, and localization. 
WT, A53T and E46K α-synuclein are membrane localized, 
whereas A30P is diffuse throughout the cytoplasm. Our low 
expression model does not show α-synuclein toxicity unless 
yeast have compromised mitochondrial oxidative stress 
response or proteasomal dysfunction (Sharma et al., 2006; 
White thesis 2007). Unfortunately, until 2008, studies in our lab 
used an α-synuclein model with an incorrect 140th amino acid. In 
WT α-synuclein the 140th amino acid should be alanine, but our 
model had glycine. This unexpected error was due to PCR-
based subcloning and faulty primer design. The mistake was 
immediately corrected in all α-synuclein constructs, but since my 
thesis began in the spring of 2007, some of my work involved 
the uncorrected α-synuclein. For the purpose of comparison, this 
thesis contains data for both α-synuclein-Glycine140 and α-
synuclein-Alanine140. 
 
Hypothesis and Aims 
My hypothesis is that the MVB/endosome pathway is a route for 
α-synuclein degradation by the lysosome. To test this 
hypothesis, I selected two genes from each ESCRT complex.  
For ESCRT-I, I chose to evaluate the role of vps28 because its 
elimination was previously shown to be toxic (Willingham et al., 
2003) and mvb12 because it was recently discovered at the time 
I began my research (Oestreich et al., 2007). For ESCRT-II, 
vps25 and vps36 were chosen randomly. Lastly, for ESCRT-
III, I chose to evaluate vps24 because its deletion was 
shown to be toxic (Willingham et al., 2003) and vps20 was 
chosen randomly. I predicted that deletion of any one of 
these genes would increase α-synuclein toxicity and change its 
localization (Figure 4). To evaluate the role of all six proteins I 
performed the following aims:  
Aim 1:  To compromise ESCRT-I genes (vps28 and 
mvb12) in budding yeast and determine whether α-synuclein 
accumulated, changed localization, and/or induced toxicity.  
Aim 2: To compromise ESCRT-II genes (vps25 and 
vps36) in budding yeast and determine whether α-synuclein 
accumulated, changed localization, and/or induced toxicity.  
 Aim 3: To compromise ESCRT-III genes (vps24 and 
vps20) in budding yeast, and determine whether α-synuclein 
accumulated, changed localization, and/or induced toxicity. 
 Aim 4: This aim evaluated whether the incorrect 
amino acid glycine would alter α-synuclein properties in parent 
or MVB pathway compromised strains (vps28Δ, vps25Δ, 
vps24Δ). The following sections include methods and materials, 
results, discussion, and conclusions of the studies that address 
the above aims. 
 
Results 
 
Experimental set up: The role of the MVB/endocytosis 
pathway in α-synuclein regulation was examined in budding 
yeast strains lacking specific genes that encode protein 
complexes ESCRT-I, II, or III. Specifically, for each ESCRT 
complex, two knockout strains were analyzed and compared 
to the isogenic parent strain BY4741: vps28Δ and mvb12Δ 
for ESCRT-I, vps25Δ and vps36Δ for ESCRT-II, and vps20Δ 
and vps24Δ for ESCRT-III. These seven yeast strains were 
transformed with five plasmid expression vectors. Two 
served as controls (pYES2 parent vector and GFP vector) 
used to corroborate that the vector alone and the addition of 
the GFP protein was not detrimental to the yeast strains. The 
three remaining vectors consisted of WT α-synuclein and α-
synuclein familial mutants A30P and E46K. All α-synuclein 
variants were tagged with GFP at the C-terminus. Four 
assays were used to assess PD-related α-synuclein 
properties. Toxicity and growth patterns were assessed by 
optical density growth curves and serial dilution spotting, 
localization was visualized by live cell fluorescence 
microscopy, and aggregation and accumulation was 
observed by Western blotting.  
	   
 
 
  
Figure 4: Hypothesis for altered α-synuclein properties in yeast with compromised MVB. A. Yeast with intact MVB/endocytosis sorting pathways will be 
healthy and α-synuclein bind the membrane. B. Yeast with compromised MVB/endocytosis pathways (vps knockouts) will form aggregates and a bind less to the 
membrane. Additionally α-synuclein will be toxic to cells. C. Table showing the genes that make ESCRT-I, II and III. The genes examined in this study have a 
checkmark. 
 
α-Synuclein is Membrane-Bound and Non-Toxic in Parent 
Strain BY4741  
First, α-synuclein was examined in parent strain BY4741, 
which served as a comparative control for all subsequent 
strains we evaluated with compromised ESCRT complexes. 
The following PD-related α-synuclein properties noted 
confirm the published findings in the field and in our lab 
(Outerio and Lindquist, 2003; Sharma et al., 2007; M. White 
thesis 2007): 1) neither WT nor familial mutants A30P and 
E46K were toxic (Figure 5A & B). 2) WT and E46K α- 
synuclein are primarily plasma membrane bound, while 
A30P was predominantly diffuse throughout the cytoplasm 
(Figure 5D & E). 3) Protein expression was similar for all α-
synuclein expressing cells (Figure C).  
 
α-Synuclein is Toxic to ESCRT-I Deficient Strain vps28Δ  
Next, we evaluated the effects of α-synuclein in ESCRT-I 
compromised yeast vps28Δ. Compared to pYES2 and GFP 
growth curves, WT, A30P, and E46K cells showed delayed 
growth in vps28Δ cells (Figure 6A). This α-synuclein-
dependent toxicity was confirmed by spotting analysis 
(Figure 6B). Importantly, α-synuclein-expressing vps28Δ 
cells exhibited compromised growth compared to parent 
strain BY4741 (compare Figure 5A to Figure 6A). These 
findings are in support of our hypothesis. Although WT and 
E46K α-synuclein localization in vps28Δ cells did not shift 
dramatically compared to BY4741, weakened membrane 
affinity and increased cytoplasmic localization was observed  
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during early expression. Over time, however, all α-synuclein 
localization patterns resembled those of parent stain BY4741 
(compare Figure 5D & E to Figure 6D & E). Finally, contrary 
to what we hypothesized, no increase in the α-synuclein 
expression in vps28Δ was seen compared to parent strain 
BY4741 levels (compare Figure 5C to Figure 6C).  
Therefore, the vps28Δ toxicity was best correlated with 
changes in α-synuclein localization. 
 
Second ESCRT-I Strain mvb12Δ Enhaces α-Synuclein 
Accumulation 
A second ESCRT-I knockout strain, mvb12Δ,  was evaluated 
to further elucidate what was seen in vps28Δ and the role of 
this first complex in the regulation of  α-synuclein. 
Surprisingly, while cells expressing α-synuclein grew equal 
to pYES2 and GFP in mvb12Δ, (Figure 7A & B).  α-
synuclein-dependent toxicity was not observed in mvb12Δ 
cells as compared to BY4741 (compare Figure 5A & B to 
Figure 7A & B). Furthermore, no change in α-synuclein 
localization was seen in mvb12Δ cells (compare Figure 5D & 
E to Figure 7D & E). However, we did see a consistent 
increase in α-synuclein expression in mvb12Δ compared to 
parent strain BY4741 (compare Figure 5C to Figure 7C). 
Therefore, while both ESCRT-I proteins affected α-synuclein, 
they affected different properties.  
 
ESCRT-II vps25Δ Strain has Subtle Effects on α-Synuclein 
Localization 
We then evaluated the role of ESCRT-II in the regulation α-
synuclein. Cells expressing  α-synuclein in vps25Δ grew 
similarly to pYES2 and GFP cells and to parent strain 
BY4741 (compare Figure 5A & B to Figure 8A & 
B). Fluorescence microscopy revealed subtle shifts in WT 
and E46K α-synuclein localization from primarily membrane-
bound in parent strain BY4741 to weak membrane-bound 
and diffuse in vps25Δ cells. A30P localization remained 
unchanged (compare Figure 5D & E to Figure 8D & E). 
Lastly, α-synuclein expression was similar in both 
vps25Δ and parent strain BY4741 (compare Figure 5C to 
Figure 8C). Therefore, only one α-synuclein property was 
subtly affected by vps25Δ.  
 
 α-Synuclein Shifts Localization and Accumulates in ESCRT-
II vps36Δ 
The second ESCRT-II gene examined was vps36Δ. All 
vps36Δ cells, including α-synuclein expressing and non-
expressing cells, had similar growth patterns (Figure 9A & 
B). Not surprisingly, all vps36Δ cells had delayed growth 
compared to parent stain BY4741 due to their decrease 
utilization of a carbon source. What was surprising, however, 
was that irrespective of α-synuclein expression the delay in 
growth was equal for all vps36Δ cells (compare Figure 5A & 
B to Figure 9A & B). Compared to BY4741, early WT and 
E46K expression shifted from their predominantly plasma 
membrane-bound localization to a variety of different 
patterns in vps36Δ cells. Phenotypes observed included 
membrane-bound with aggregates, punctate foci, and 
intracellular foci surrounding the vacuole or diffuse 
throughout the cytoplasm. Over time, however, WT and 
E46K became primarily membrane-bound. Although A30P 
was predominantly diffuse throughout the cytoplasm, in later 
expressing cells A30P appeared more heterogeneous: as 
membrane bound with diffuse α-synuclein or punctate foci 
(compare Figure 5D & E to Figure 9D & E). Additionally, all 
α-synuclein variants accumulated in vps36Δ (compare 
Figure 5C to Figure 9C). Therefore, ESCRT-II proteins 
impacted α-synuclein differently.  
 
 
ESCRT-III vps20Δ Behaves Similarly to ESCRT-II vps36Δ  
Our final goal was to evaluate the role of ESCRT-III proteins 
in mediating α-synuclein degradation. vps20Δ cells displayed 
a non-α-synuclein-dependent delay in growth compared to 
parent strain BY4741, much like ESCRT-II vps36Δ cells 
(compare Figure 5A & B to Figure 10A & B). This strain also 
has decreased carbonsource utilization (Cheng et al., 2007). 
Additionally, WT and E46K localization was predominantly 
membrane bound; however, other expression patterns such 
as membrane-bound with intracellular aggregates 
surrounding the vacuole and membrane-bound with 
aggregates were also present during early expression. A30P 
localization patterns remained unchanged compared to 
those of parent stain BY4741 (compare Figure 5D & E to 
Figure 10D & E). As seen in previous strains 
(mvb12Δ and vps36Δ), α-synuclein also accumulated in 
vps20Δ (compare Figure 5C to Figure 10C).  
 
Second ESCRT-III Strain vps24Δ is Toxic to A30P and 
Alters Localization 
Unexpectedly, the second ESCRT-III strain vps24Δ did not 
have similar effects on α-synuclein as the first evaluated 
strain vps20Δ. Toxicity in this strain was specific to A30P-
expressing cells, which had delayed growth compared to 
parent strain BY4741. WT and E46K-expressing cells grew 
similarly to pYES2, GFP, and parent strain BY4741 
(compare Figure 5A & B to Figure 11A & B). Furthermore, 
WT and E46K shifted from their membrane-bound 
localization to a strong expression within the cytoplasm. 
A30P localization patterns remained unchanged (compare 
Figure 5D & E to Figure 11D & E). Finally, no accumulation 
was seen compared to parent strain BY4741 (compare 
Figure 5C to Figure 11C). Therefore, both ESCRT-III 
proteins play a role in all three PD-related α-synuclein 
properties. 
 
The Role of α-Synuclein’s Last Amino Acid 
Last summer, we realized that our budding yeast were 
transformed with α-synuclein’s expressing vector containing 
a point mutation in its last amino acid. This unexpected error 
was due to PCR-based subcloning that utilized a faulty 
primer sequence. The mutation consisted of an alanine to 
glycine switch in the 140th amino acid. After this discovery, 
we immediately corrected the amino acid sequence and re-
transformed all the budding yeast strains with the corrected 
sequence. Prior to realizing this error, however, many 
ESCRT knockout strains had been evaluated: vps28Δ and 
mvb12Δ for ESCRT-I, vps25Δ for ESCRT-II, and vps24Δ for 
ESCRT-III. This unexpected error, however, provided us with 
a tool to examine the importance of the 140th amino acid in 
α-synuclein properties and PD. 
 A comparison between α-synuclein-Glycine140 
and α-synuclein-Alanine140 revealed no changes between 
the vast majority of yeast strains examined. A small set of 
strains did, however, exhibit subtle differences between the 
two α-synuclein sequences. The observed findings are 
summarized below:  
 
1. Growth curves were similar for α-synuclein-Alanine140 
and α-synuclein-Glycine140 mvb12Δ and vps25Δ. A 
difference was observed in vps28Δ cells where α-synuclein-
Alanine140 was toxic, whereas α-synuclein-Glycine140 was 
not. The only change in vps24Δ cells was the observation of 
A30P-dependent toxicity in the cells expressing α-synuclein-
Alanine140.  
	  
2. Localization patterns were mostly consistent between α-
synuclein-Glycine140 and α-synuclein-Alanine140 
	  expressing cells. Differences observed were contained to 
vps28Δ and vps24Δ cells (compare Figures 6 and 10 to 
Appendix Figures 2 and 4). 
 
3. Accumulation patterns were also consistent between α-
synuclein-Alanine140 and α-synuclein-Glycine140 
expressing cells with the exception of parent strain BY4741. 
In this strain, E46K α-synuclein-Glycine140 expression was 
never detected, however E46K α-synuclein-Alanine140 was 
present in all strains (compare Figures 5 to Appendix Figure 1). 
 
Discussion  
How α-synuclein is degraded by cells is an unresolved, 
therapeutically relevant issue for the future treatment of PD. 
Until recently, most of the studies in the field suggested that α-
synuclein was degraded by the proteasome (Rideout et al., 
2001; Chen et al., 2006). In recent years, however, 
pharmacological evidence suggests that α-synuclein can also be 
degraded by the lysosome (Lee et al., 2004; Cuervo et al., 2004; 
Willingham et al., 2003; Kuwahara et al., 2008). The goal of my 
thesis was to provide genetic evidence for the MVB/endocytosis 
pathway as a regulator of α-synuclein degradation. We 
previously hypothesized that some budding yeast strains lacking 
specific ESCRT genes would exhibit α-synuclein-dependent 
toxicity and cause α-synuclein to accumulate and mislocalize. 
From the six out of eleven ESCRT genes examined 
thus far, we have come to three conclusions that are worth 
further discussion: 1) genetic evidence supports that the 
MVB/endocytosis pathway is implicated in α-synuclein 
degradation; 2) although all ESCRT genes tested alter α-
synuclein properties, some have only subtle effects on α-
synuclein; 3) α-synuclein toxicity is surprisingly rare.  
 
MVB/endocytosis Pathway is Implicated in α-Synuclein 
Degradation 
Our first major finding is that we provide genetic evidence that 
the genes controlling the MVB/endocytosis pathway regulate 
PD-related α-synuclein properties. These data provide new 
and needed evidence to strengthen the notion that the 
lysosome is a site for α-synuclein degradation. For example, 
while not all knockout strains had the same effects on α-
synuclein, five out of the six strains evaluated caused α-
synuclein accumulation and/or shifts in its localization patterns 
(vps28Δ, mvb12Δ, vps36Δ, vps25Δ, and vps20Δ). On the other 
hand, only two strains were toxic (vps28Δ and vps24Δ). These 
findings are in agreement with Willingham et al. (2003; Table 2).  
We were somewhat surprised that none of the 
evaluated ESCRT genes regulated all α-synuclein properties 
examined (toxicity, accumulation, and localization). However, 
this tendency to not affect all pathologically-relevant properties 
has been previously observed. For example, deletion of the heat 
shock protein Sac3 is toxic to yeast; this deletion, however, has 
no effect on α-synuclein accumulation (Flower et al., 2005). 
Furthermore, overexperssion strains also show alterations in 
a single property while leaving the rest unaffected. In yeast, 
overexpression of Ypk9, an uncharacterized yeast gene, 
suppresses α-synuclein-induced toxicity; however, 
accumulation in these strains is unchanged compared to the 
control (Gitler et al., 2009). In our lab, compromised oxidative 
stress response strain sod2Δ shows consistent toxic effects, but 
no change in localization patterns (Brandis thesis, 2006).  
Furthermore, most other labs focus primarily on 
one α-synuclein property while neglecting to report others 
(Table 3). For example, Willingham et al. (2003) identified 86 
genes that enhanced α-synuclein toxicity when deleted. 
Toxicity was evaluated exclusively by serial spotting analysis 
while α-synuclein accumulation and localization were not 
addressed. Therefore, alteration of one or two properties is not 
unexpected and is generally found to be sufficient evidence to 
suggest the role of ESCRT proteins in α-synuclein regulation.  
Nevertheless, as an experimental standard, our lab investigates 
all three. 
 
Some ESCRT Genes Subtly Regulate α-Synuclein Properties 
Our second notable finding is that not all ESCRT genes appear 
to regulate α-synuclein to the same extent. ESCRT-II vps25Δ 
strain had minimal effect on α-synuclein localization, whereas 
mvb12Δ had a minor effect on α-synuclein accumulation 
compared to parent strain BY4741. In these strains, all other α-
synuclein properties remained unchanged. For reasons 
explained below, we were not surprised by these results. 
As shown by Bowers et al. (2005), ESCRT-II-deficient 
mammalian cells are capable of properly degrading a model 
substrate protein, EGFR. Specifically, the depletion of vps25 
and vps22 has no effect on EGFR down-regulation. Additionally, 
they found that ESCRT-II is not necessary for the degradation of 
MVB/endocytosis pathway substrates. Furthermore, ESCRT-II 
consists of vps22, vps36, and two vps25 proteins; however, 
interactions are strongest between vps22 and vps36 (Slater et 
al., 2006). Therefore, ESCRT-II, specifically the vps25, protein is 
most dispensable in the regulation of mammalian 
MVB/endocytosis pathway substrates. In our PD yeast model 
loss of vps25 may be compensated by the interactions between 
vps22 and vps36. This provides an explanation as to why 
vps25, when depleted, did not dramatically alter α-synuclein 
properties. Another body of evidence suggests that vps deletion 
strains do not necessarily behave similarly. For example, 
Bowers et al. (2009) found that under different salt conditions 
some deletion strains were viable, while other were not. More 
specifically, yeast strains lacking vps23, vps28, vps25, vps36, or 
vps20 were sensitive to lithium chloride, whereas vps37, vps2, 
vps24, or vps27 were not. Ultimately, removal of one protein in 
the MVB/endocytosis pathway may not be enough to inhibit the 
degradation of a specific substrate, a phenomenon that may be 
occurring in our yeast models lacking vps25 and mvb12.  
 
Understanding Toxic Differences  
The third notable finding is that, unexpectedly, most ESCRT 
knockout strains did not exhibit toxic effects on α-synuclein. In 
fact, four out of the six strains evaluated did not alter growth 
patterns compared to parent strain BY4741 (mvb12Δ, vps25Δ, 
vps36Δ, and vps20Δ). While vps28Δ cells exhibited α-synuclein-
dependent toxicity for all α-synuclein variants, vps24Δ was only 
toxic to A30P-expressing cells. After evaluating a list of 
previously examined knockout yeast strains by our lab, we 
realized that α-synuclein-dependent toxicity is rarely observed 
(Table 4A). Furthermore, a genetic screen revealed that only 86 
out of approximately 4,000 knockout strains induced α-
synuclein toxicity in yeast (Table 4B). 
We chose to evaluate A30P toxicity separately 
because, unlike WT and E46K, this familial mutant has unique 
properties and is predominantly localized to the cytoplasm 
(Sharma et al., 2007; Outerio and Lindquist, 2003). Additionally, 
while overexpression of WT and E46K is toxic to yeast, 
overexpression of A30P is not (Dixon et al., 2005; Outerio and 
Lindquist, 2003). Interestingly, Flower et al. (2009) found that 
YPPI, an essential gene in yeast of unknown function, 
exclusively suppresses A30P toxicity and facilitates its transport 
to the vacuole for degradation. This gene had no effect on WT 
α-synuclein or other familial mutants. Much like WT and E46K, 
A30P was toxic in vps28Δ; however, it was also toxic in vps24Δ. 
Therefore, A30P toxicity is dependent upon the manipulation of 
specific genes. In our study, deletion on vps28 and vps24 was 
enough to induce A30P toxicity.  
Due to similar WT and E46K α-synuclein localization 
properties, toxicity was evaluated jointly. WT and E46K α-
synuclein-expressing cells were toxic in vps28Δ. In addition to 
	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Summary of α-synuclein properties in endocytosis-deficient strains. α-Synuclein toxicity, localization, and accumulation were evaluated for 
all six ESCRT protein knockout strains. Changes were assessed as a strong, weak or none. 
  
Table 3: Summary of α-synuclein properties assessed in published yeast models. This table indicates whether one, two, or all three α-synuclein 
properties were assessed by other studies. Properties evaluated are indicated by a yes, while properties not evaluated are indicated by a no.  
	  Table 4: Summary of α-synuclein toxicity in yeast deletion strains. A. Number yeast deletion strains that induced α-synuclein-dependent toxicity in 14 
different studies in the DebBurman lab. B. Number of yeast deletion strains that induced α-synuclein-dependent toxicity from a genetic screen of ~4000 strains. 
 
 
cytoplasmic localization there was still membrane-bound α-
synuclein whenever toxicity was present. Contrary to this, in 
vps24Δ, WT and E46K shifted to a strong cytoplasmic 
localization and did not show toxicity. Correlations between 
membrane affinity and toxicity have previously been 
documented. For example, mutant α-synuclein, causing a 
decrease in membrane affinity, promotes survival in yeast 
(Volles and Lansbury, 2007). Similarly, membrane-binding 
WT and A53T familial mutants are toxic to yeast when 
overexpressed (Dixon et al., 2005). When overexpressed, 
A30P remains in the cytoplasm and is not toxic. We believe 
that WT and E46K toxicity is dependent on membrane 
localization. However, membrane binding alone is not 
sufficient for toxicity. Many of the strains I evaluated retained 
membrane affinity but did not show toxicity 
(mvb12Δ, vps20Δ, vps36Δ, and vps25Δ). Thus, the necessary 
amount of membrane binding needed for cells to reach their 
toxicity threshold remains unclear.  
Furthermore, we believe that the proteasome is 
compensating for the compromised MVB/endocytosis pathway 
in the strains exhibiting no growth impairment and a shift in α-
synuclein’s localization to the cytoplasm (vps25Δ, vps36Δ, 
vps24Δ and vps20Δ).  Many studies show compensatory effects 
between the proteasome and lysosome when needed. For 
example, Laszlo et al. (1992) found that mammalian prion PrP is 
deposited in the lysosome of mice brains; however, in yeast,  
 
PrP also accumulates in the cytoplasm when the proteasome is 
inhibited (Ma and Lindquist, 2001). In addition, molecules 
usually degraded by the lysosome can enter the proteasome 
pathway during incomplete autophagy (Settembre et al., 2007).  
Thus, when needed the two degradation pathways may be 
interchangeable. Additionally, α-synuclein degradation in the 
proteasome is well documented, and the shift to the cytoplasm 
places α-synuclein in an ideal site for proteasome degradation. 
Finally, our vps24Δ was not toxic to WT α-synuclein as 
observed Willingham et al. (2003). This discrepancy may be due 
to their higher α-synuclein expression in yeast.  
The Role of the 140th Amino Acid 
Our fourth finding is that the 140th amino acid is negligible for 
PD-related α-synuclein properties. These findings were 
expected since the switch from the alanine to glycine occurred 
at the last amino acid which rarely contributes to the structure of 
a protein. The difference between α-synuclein-Glycine140 and 
α-synuclein-Alanine is a methyl group, which is a neutral group 
that is of relative small size compared to the α-synuclein protein. 
Furthermore, unlike other amino acids in the α-synuclein protein, 
the 140th amino acid is not known to undergo post-translational 
modifications (Anderson et al., 2006).  
Rarely, subtle differences were observed between α-
synuclein-Glycine and α-synuclein-Alanine140. The differences 
	  observed were in parent strain BY4741 E46K expression, 
vps24Δ toxicity, and vps28Δ localization and toxicity. Therefore, 
the research conducted prior to the discovery of the error is 
relevant and both α-synuclein sequences behave similarly.  
Critiques and Limitations 
The findings in this thesis are limited by the absence of key 
experiments. We have not yet performed a vacuolar stain in 
order to verify that α-synuclein is not transported to the vacuole. 
Furthermore, a vesicle stain is needed to evaluate the integrity 
of the MVB/endocytosis pathway. Finally, we have not 
completed immunoprecipitation assays to assess interactions 
between MVB proteins and α-synuclein.  
Future Directions 
Future research will complete analysis on remaining ESCRT-I 
(vps23 and vps37), II (vps22) and III (vps2 and vps32) proteins 
and their ability to regulate α-synuclein toxicity, localization, 
misfolding, and accumulation. This will help us better 
understand the MVB/endocytosis pathway and its role in α-
synuclein degradation. To further our research, we would like to 
develop vesicle and vacuolar stains in order to visualize α-
synuclein and its route to the lysosome. Also, we would like to 
test synergistic effects by combining MVB dysfunction with 
either pharmacologically compromised proteasomes or induced 
oxidative stress. We suspect that the proteasome is 
compensating for lysosomal loss, thus we expect to see α-
synuclein-specific toxicity in cells which have compromised 
proteasomes and lysosomes. Another possibility would be to 
verify whether proteasomal enzyme expression increases in the 
strains where WT and E46K shifted to the cytoplasm. Finally, we 
aim to evaluate induction of apoptosis, autophagy, and vacuolar 
integrity as cellular responses in MVB-deficient cells expressing 
α-synuclein. 
Conclusion 
The cause of α-synuclein degradation is a puzzling question that 
remains unanswered. A likely contributor to the onset of this 
neurodegenerative disease is the accumulation and aggregation 
of the α-synuclein protein. For many years now, scientists have 
sought to find mediators of α-synuclein in the hopes of 
understanding the pathogenesis behind PD. If the cause of PD 
is in fact α-synuclein and its aggregated form, then duty lies in 
understanding how this protein is removed from cells and why it 
is not properly degraded in PD patients. It was thus my goal to 
further understand the role of the MVB/endocytosis pathway in 
the degradation of α-synuclein. The use of a yeast model was 
ideal for this project because genes of the MVB/endocytosis 
pathway were first discovered in yeast. Additionally, yeast have 
shown to be a great model for studying this pathway and the 
substrates that use it.  
After examining α-synuclein properties (toxicity, 
localization, and accumulation) in six ESCRT-deficient budding 
yeast strains, we are confident that the MVB/endocytosis 
pathway is a route for α-synuclein degradation. Even though 
alterations in all three properties evaluated where never 
observed at once, we were able to see changes in α-synuclein 
localization and/or expression in all knockout strains compared 
to those of parent strain BY4741. Furthermore, α-synuclein-
dependent toxicity was observed in one ESCRT-deficient strain. 
Combining the outcomes of all the knockout strains provided a 
complex picture of the role of MVB/endocytosis pathway in 
regulating α-synuclein. 
 
Methods and Materials  
Methods from Sharma et al. 2006. 
“α-Synuclein Constructs  
Human wild-type and A53T mutant α-synuclein cDNAs were a gift from 
Christopher Ross (Johns Hopkins University).  A30P and E46K were 
created from wild-type and α-synuclein using site-directed mutagenesis 
(Invitrogen) and mutations were confirmed by sequencing (University of 
Chicago).  Wild-type and mutant α-synuclein cDNAs were subcloned into 
the pYES2.1/V5-His-TOPO yeast expression vector (Invitrogen).  All α-
synuclein forms were tagged with GFP using a two-step cloning strategy, 
with GFP either tagged at the N- or C-terminus. α-Synuclein cDNAs were 
first subcloned into mammalian expression vectors, pcDNA3.1/C-terminal 
GFP (Invitrogen) in order to be fused with GFP at the C-terminus. GFP 
tagged α-synuclein genes were then PCR-amplified and subcloned into 
pYES2.1/V5-His-TOPO yeast expression vector (Invitrogen). Chemically 
competent E. coli cells were transformed with the α-synuclein, α-
synuclein-GFP, and GFP-α-synuclein pYES2.1/V5-His-TOPO vectors. 
The parent pYES2.1 vector (Invitrogen) and GFP in pYES2.1/V5-His-
TOPO vector were used as controls. 
 
Correcting the 140th Amino Acid Mutant  
All α-synuclein-Glycine140 was reconstructed to α-synuclein-Alanine140 
using site-directed mutagenesis. The following primers were used:  
     Gal-1 forward primer 5’-AATATACCTCTATACTTTAACGTC-3’ 
     V5C-term Reverse primer 5’-ACCGAGGAGAGGGTTAGGGAT-3” 
All α-synuclein constructs were confirmed by sequencing at University of 
Chicago.  
 
Yeast Strains 
Parent strain BY4741 (mat a) and MVB knockout strains vps28Δ, 
mvb12Δ, vps25Δ, vps36Δ, vps20Δ, and vps24Δ were purchased from 
Open Biosystems. 
 
Yeast Expression 
α-Synuclein expression plasmid vectors were transformed into the above 
budding yeast strains as described (Burke et al. 2000). For selection, 
yeast cells were grown on synthetic-complete media lacking uracil (SC-
Ura). Table 1 summarizes all transformed stains used in this study. 
Presence of α-synuclein constructs was confirmed by PCR. The pYES2.1 
vector, containing a galactose inducible promoter (GAL1), allowed for 
regulated α-synuclein expression.  Yeast cells were first grown overnight 
in SC-Ura glucose (2%) or SC-Ura raffinose (2%) media at 30°C and then 
spun in a centrifuge at 200 rpm.  Cells were washed with water and diluted 
to log-phase (5 x 10^6 cells/ml) in SC-URA galactose (2%) media to 
induce expression and grown to the time points desired for various 
measurements.     
 
Western Analysis 
Yeast cells (2.5x10 7 cells/mL) were washed in 50 mM Tris (pH 7.5), 10 
mM NaN3 and solubilized in Electrophoresis Sample Buffer (ESB; Burke, 
2000) containing 2% sodium dodecyl sulfate (SDS), 80 mM Tris (Ph 6.8), 
10% glycerol, 1.5% dithiothreitol, 1 mg/ml bromophenol blue, and a 
cocktail of protease inhibitors and solubilizing agents (1% Triton-X 100, 1 
mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 mM sodium 
orthovanadate, 0.7 mg/ml pepstatin A, 0.5 mg/ml leupeptin, 10 mg/ml E64, 
2mg/ml aprotinin, and 2 mg/ml chymostatin). Samples were run on pre-
cast 10-20% Tris-Glycine gels (Invitrogen) using SDS containing running 
buffer. SeeBlue (Invitrogen) was used as the molecular standard. Gels 
were transferred to PVDF membranes and Western blot was performed 
with different monoclonal antibodies using standard protocols and 
detected for alkaline phosphatase activity: anti-V5 (Invitrogen) and anti-
phosphoglycerokinase (PGK; Molecular Probes) for most expression 
experiments, as a measure of loading control in duplicate blots. 
 
Growth Curve Analysis 
Cells were grown in 10 ml SC-URA glucose overnight at 30°C, 200 rpm. 
Cells were harvested at 1500 x g for 5 min at 4°C, and were washed twice 
in 5 ml H20. Cells were re-suspended in 5 mL H20 and were counted. 
Flasks with 25 ml SC-URA galactose were each inoculated to 2.0x106 
cells/ml density. At 0, 3, 6, 12, 18, 24, 36 and 48 hours, and in duplicate 
measurements, 1 ml of cell culture was removed and placed in a cuvet to 
measure absorbance using a Hitachi U-2000 Spectrophotometer. 
Averaged absorbance readings were plotted against time to produce a 
growth curve.  
 
GFP Microscopy 
Cells were grown overnight in 10 ml SC-URA glucose at 30°C at 200 rpm. 
Protein expression was induced with SC-URA galactose media. After a 
time specific induction, cells were harvested at 1500 x g at 4° C for 5 
minutes and were washed twice with 5 ml H20. Cells were re-suspended 
in 100-1000 ml SC-URA glucose, and 10 ml cell suspension was pipeted 
	  onto a slide. Cells were visualized using a Nikon TE2000-U fluorescent 
microscope and images were acquired and analyzed using Metamorph 
4.0 imaging software.” 
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